REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT (Q2035362)
Jump to navigation
Jump to search
Project Q2035362 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | REVER3BAB: AN INNOVATIVE BIOLOGICAL MEDICINE FOR REVERTIRE THE RESISTANCE TO CONVENTIONAL CANCER TREATMENT |
Project Q2035362 in Italy |
Statements
409,635.99 Euro
0 references
829,236.6 Euro
0 references
49.4 percent
0 references
28 December 2017
0 references
4 December 2019
0 references
6 July 2019
0 references
ISTITUTI FISIOTERAPICI OSPITALIERI - IFO
0 references
TAKIS SRL
0 references
ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
REVER3MAB: UN ANTICORPO MONOCLONALE DIRETTO CONTRO LA PROTEINA ERBB3 IN GRADO DI BLOCCARE LA PROLIFERAZIONE DELLE CELLULE TUMORALI IN VITRO E IN VIVO, CON POTENZIALE USO COME AGENTE TERAPEUTICO IN CLINICA. (Italian)
0 references
REVER3BAB: A MONOCLONAL ANTIBODY AGAINST THE ERBB3 PROTEIN CAPABLE OF BLOCKING IN VITRO AND IN VIVO CANCER CELLS, WITH POTENTIAL USE AS A THERAPEUTIC AGENT IN CLINICAL USE. (English)
0.0024910949105437
0 references
REVER3MAB: UN ANTICORPS MONOCLONAL DIRIGÉ CONTRE LA PROTÉINE ERBB3 QUI PEUT BLOQUER LA PROLIFÉRATION DES CELLULES TUMORALES IN VITRO ET IN VIVO, AVEC UNE UTILISATION POTENTIELLE COMME AGENT THÉRAPEUTIQUE EN CLINIQUE. (French)
16 December 2021
0 references
REVER3MAB: EEN MONOKLONAAL ANTILICHAAM GERICHT TEGEN HET ERBB3-EIWIT DAT DE PROLIFERATIE VAN TUMORCELLEN IN VITRO EN IN VIVO KAN BLOKKEREN, MET POTENTIEEL GEBRUIK ALS THERAPEUTISCH MIDDEL IN DE KLINIEK. (Dutch)
23 December 2021
0 references
REVER3MAB: EIN MONOKLONALER ANTIKÖRPER, DER GEGEN DAS ERBB3-PROTEIN GERICHTET IST, DER DIE PROLIFERATION VON TUMORZELLEN IN VITRO UND IN VIVO BLOCKIEREN KANN, MIT POTENZIELLER ANWENDUNG ALS THERAPEUTISCHES MITTEL IN DER KLINIK. (German)
24 December 2021
0 references
REVER3MAB: ANTICUERPO MONOCLONAL DIRIGIDO CONTRA LA PROTEÍNA ERBB3 QUE PUEDE BLOQUEAR LA PROLIFERACIÓN DE CÉLULAS TUMORALES IN VITRO E IN VIVO, CON POTENCIAL USO COMO AGENTE TERAPÉUTICO EN LA CLÍNICA. (Spanish)
25 January 2022
0 references
REVER3BAB: ET MONOKLONALT ANTISTOF MOD ERBB3-PROTEINET, DER KAN BLOKERE IN VITRO- OG IN VIVO-KRÆFTCELLER, MED POTENTIEL ANVENDELSE SOM TERAPEUTISK MIDDEL I KLINISK BRUG. (Danish)
5 July 2022
0 references
REVER3BAB: ΜΟΝΟΚΛΩΝΙΚΌ ΑΝΤΊΣΩΜΑ ΚΑΤΆ ΤΗΣ ΠΡΩΤΕΪ́ΝΗΣ ERBB3 ΙΚΑΝΌ ΝΑ ΑΝΑΣΤΈΛΛΕΙ ΤΑ ΚΑΡΚΙΝΙΚΆ ΚΎΤΤΑΡΑ IN VITRO ΚΑΙ IN VIVO, ΜΕ ΠΙΘΑΝΉ ΧΡΉΣΗ ΩΣ ΘΕΡΑΠΕΥΤΙΚΌΣ ΠΑΡΆΓΟΝΤΑΣ ΣΕ ΚΛΙΝΙΚΉ ΧΡΉΣΗ. (Greek)
5 July 2022
0 references
REVER3BAB: MONOKLONSKO PROTUTIJELO PROTIV PROTEINA ERBB3 KOJE MOŽE BLOKIRATI STANICE RAKA IN VITRO I IN VIVO, S POTENCIJALNOM PRIMJENOM KAO TERAPEUTSKI LIJEK U KLINIČKOJ PRIMJENI. (Croatian)
5 July 2022
0 references
REVER3BAB: UN ANTICORP MONOCLONAL ÎMPOTRIVA PROTEINEI ERBB3 CAPABIL SĂ BLOCHEZE CELULELE CANCEROASE IN VITRO ȘI IN VIVO, CU POTENȚIALA UTILIZARE CA AGENT TERAPEUTIC ÎN UZ CLINIC. (Romanian)
5 July 2022
0 references
REVER3BAB: MONOKLONÁLNA PROTILÁTKA PROTI PROTEÍNU ERBB3 SCHOPNÁ BLOKOVAŤ RAKOVINOVÉ BUNKY IN VITRO A IN VIVO S POTENCIÁLNYM POUŽITÍM AKO TERAPEUTICKÁ LÁTKA PRI KLINICKOM POUŽITÍ. (Slovak)
5 July 2022
0 references
REVER3BAB: ANTIKORP MONOKLONALI KONTRA L-PROTEINA ERBB3 LI KAPAĊI JIMBLOKKA ĊELLOLI TAL-KANĊER IN VITRO U IN VIVO, B’UŻU POTENZJALI BĦALA AĠENT TERAPEWTIKU FL-UŻU KLINIKU. (Maltese)
5 July 2022
0 references
REVER3BAB: ANTIPO MONOCLONAL CONTRA A PROTEÍNA ERBB3 CAPACITÁVEL DE BLOQUEAR CÉLULAS DE CÂNCER IN VITRO E IN VIVO, COM UTILIZAÇÃO POTENCIAL COMO AGENTE TERAPÉTICO DE UTILIZAÇÃO CLÍNICA. (Portuguese)
5 July 2022
0 references
REVER3BAB: MONOKLONAALINEN VASTA-AINE ERBB3-PROTEIINIA VASTAAN, JOKA PYSTYY SALPAAMAAN IN VITRO JA IN VIVO SYÖPÄSOLUJA JA MAHDOLLISESTI KÄYTTÄÄ TERAPEUTTISENA AINEENA KLIINISESSÄ KÄYTÖSSÄ. (Finnish)
5 July 2022
0 references
REVER3BAB: PRZECIWCIAŁO MONOKLONALNE PRZECIWKO BIAŁKU ERBB3 MOGĄCE BLOKOWAĆ KOMÓRKI NOWOTWOROWE IN VITRO I IN VIVO, KTÓRE MOGĄ BYĆ STOSOWANE JAKO ŚRODEK TERAPEUTYCZNY W ZASTOSOWANIACH KLINICZNYCH. (Polish)
5 July 2022
0 references
REVER3BAB: MONOKLONSKO PROTITELO PROTI BELJAKOVINI ERBB3, KI LAHKO IN VITRO IN IN VIVO BLOKIRA RAKAVE CELICE, KI SE LAHKO UPORABLJAJO KOT TERAPEVTSKO SREDSTVO PRI KLINIČNI UPORABI. (Slovenian)
5 July 2022
0 references
REVER3BAB: MONOKLONÁLNÍ PROTILÁTKA PROTI PROTEINU ERBB3 SCHOPNÁ BLOKOVAT NÁDOROVÉ BUŇKY IN VITRO A IN VIVO S MOŽNÝM POUŽITÍM JAKO TERAPEUTICKÉ ČINIDLO PŘI KLINICKÉM POUŽITÍ. (Czech)
5 July 2022
0 references
REVER3BAB: MONOKLONINIS ANTIKŪNAS PRIEŠ ERBB3 BALTYMĄ, GALINTIS BLOKUOTI IN VITRO IR IN VIVO VĖŽINES LĄSTELES, KURIS GALI BŪTI NAUDOJAMAS KAIP GYDOMASIS PREPARATAS KLINIKINIAM NAUDOJIMUI. (Lithuanian)
5 July 2022
0 references
REVER3BAB: MONOKLONĀLA ANTIVIELA PRET ERBB3 PROTEĪNU, KAS SPĒJ BLOĶĒT IN VITRO UN IN VIVO VĒŽA ŠŪNAS, UN TO VAR IZMANTOT KĀ TERAPEITISKU LĪDZEKLI KLĪNISKAJĀ LIETOŠANĀ. (Latvian)
5 July 2022
0 references
REVER3BAB: МОНОКЛОНАЛНО АНТИТЯЛО СРЕЩУ ПРОТЕИНА ERBB3, СПОСОБЕН ДА БЛОКИРА IN VITRO И IN VIVO РАКОВИТЕ КЛЕТКИ, С ПОТЕНЦИАЛНА УПОТРЕБА КАТО ТЕРАПЕВТИЧЕН АГЕНТ ПРИ КЛИНИЧНА УПОТРЕБА. (Bulgarian)
5 July 2022
0 references
REVER3BAB: AZ ERBB3 FEHÉRJE ELLENI MONOKLONÁLIS ANTITEST, AMELY KÉPES IN VITRO ÉS IN VIVO RÁKOS SEJTEK GÁTLÁSÁRA, KLINIKAI ALKALMAZÁS ESETÉN TERÁPIÁS SZERKÉNT TÖRTÉNŐ ALKALMAZÁS MELLETT. (Hungarian)
5 July 2022
0 references
ATHBHREITHNIÚ 3BAB: ANTASHUBSTAINT MHONACLÓNACH I GCOINNE PHRÓITÉIN ERBB3 ATÁ IN ANN CEALLA AILSE IN VITRO AGUS IN VIVO A BHLOCÁIL, LE HÚSÁID FHÉIDEARTHA MAR GHNÍOMHAIRE TEIRIPEACH IN ÚSÁID CHLINICIÚIL. (Irish)
5 July 2022
0 references
REVER3BAB: EN MONOKLONAL ANTIKROPP MOT ERBB3-PROTEINET SOM KAN BLOCKERA CANCERCELLER IN VITRO OCH IN VIVO, MED POTENTIELL ANVÄNDNING SOM TERAPEUTISKT MEDEL VID KLINISK ANVÄNDNING. (Swedish)
5 July 2022
0 references
REVER3BAB: ERBB3 VALGU MONOKLONAALNE ANTIKEHA, MIS ON VÕIMELINE BLOKEERIMA IN VITRO JA IN VIVO VÄHIRAKKE, MIDA VÕIB KASUTADA KLIINILISES RAVIAINENA. (Estonian)
5 July 2022
0 references
ROMA
0 references
8 April 2023
0 references
Identifiers
F87H18000370007
0 references